Erratum to: Effect of circulating tumor cells combined with negative enrichment and CD45-FISH identification in diagnosis, therapy monitoring and prognosis of primary lung cancer[Medical Oncology, (2014), 31, 240, DOI:10.1007/s12032-014-0240-0];Effect of circulating tumor cells combined with negative enrichment and CD45-FISH identification in diagnosis, therapy monitoring and prognosis of primary lung cancer

Medical Oncology

Volumn 31, Issue 12, 2014, Pages 1-9

  Chen, Yang Yang ^a   Xu, Guo Bin ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

CD45 FISH; CTCs; Diagnosis; Primary lung cancer; Prognosis; Treatment monitoring

Indexed keywords

ANTINEOPLASTIC AGENT; CD45 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; PTPRC PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; LUNG CANCER; LUNG DISEASE; LUNG METASTASIS; MALE; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; BLOOD; DIAGNOSTIC USE; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PHYSIOLOGIC MONITORING; PROCEDURES; PROGNOSIS; TUMOR EMBOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD45; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84919902906     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-015-0629-4     Document Type: Erratum

References (26)

1. Sher YP, Shih JY, Yang PC, et al. Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes. Clin Cancer Res. 2005;11:173–9.
2. Socinski MA, Evans T, Gettinger S, et al. Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e341S–68S.
3. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287–312.
4. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett. 2007;253:180–204.
5. Woelfle U, Sauter G, Santjer S, Brakenhoff R, Pantel K. Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer. Clin Cancer Res. 2004;10:2670–4.
6. Chen Q, Ge F, Cui W, et al. Lung cancer circulating tumor cells isolated by the EpCAM-independent enrichment strategy correlate with Cytokeratin 19-derived CYFRA21-1 and pathological staging. Clin Chim Acta. 2013;419:57–61.
7. Ning N, Zhan T, Zhang Y, et al. Improvement of specific detection of circulating tumor cells using combined CD45 staining and fluorescence in situ hybridization. Clin Chim Acta. 2014;433C:69–75.
8. Ntouroupi TG, Ashraf SQ, McGregor SB, et al. Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope. Br J Cancer. 2008;99:789–95.
9. Johnson TM, Kuffel DG, Dewald GW. Detection of hyperdiploid malignant cells in pleural effusions with chromosome-specific probes and fluorescence in situ hybridization. Mayo Clin Proc. 1996;71:643–8.
10. Tanaka F, Yoneda K, Kondo N, et al. Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res. 2009;15:6980–6.
11. Wu C, Hao H, Li L, et al. Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. J Thorac Oncol. 2009;4:30–6.
12. Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 2011;29:1556–63.
13. Katz RL, He W, Khanna A, et al. Genetically abnormal circulating cells in lung cancer patients: an antigen-independent fluorescence in situ hybridization-based case-control study. Clin Cancer Res. 2010;16:3976–87.
14. Swennenhuis JF, Tibbe AG, Levink R, Sipkema RC, Terstappen LW. Characterization of circulating tumor cells by fluorescence in situ hybridization. Cytom A. 2009;75:520–7.
15. Pecot CV, Bischoff FZ, Mayer JA, et al. A novel platform for detection of CK+and CK− CTCs. Cancer Discov. 2011;1:580–6.
16. Ntouroupi TG, Ashraf SQ, McGregor SB, et al. Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope. Br J Cancer. 2008;99:789–95.
17. Zhang Y, Wang F, Ning N, et al. Patterns of circulating tumor cells identified by CEP8, CK and CD45 in pancreatic cancer. Int J Cancer 2014. doi:10.1002/ijc.29070.
18. Wendel M, Bazhenova L, Boshuizen R, et al. Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology. Phys Biol. 2012;9:16005.
19. The American Thoracic Society and The European Respiratory Society. Pretreatment evaluation of non-small-cell lung cancer. Am J Respir Crit Care Med. 1997;156:320–32.
20. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–94.
21. Naito T, Tanaka F, Ono A, et al. Prognostic impact of circulating tumor cells in patients with small cell lung cancer. J Thorac Oncol. 2012;7:512–9.
22. Allen JE, Saroya BS, Kunkel M, et al. Apoptotic circulating tumor cells (CTCs) in the peripheral blood of metastatic colorectal cancer patients are associated with liver metastasis but not CTCs. Oncotarget. 2014;5:1753–60.
23. Chinen LT, de Carvalho FM, Rocha BM, et al. Cytokeratin-based CTC counting unrelated to clinical follow up. J Thorac Dis. 2013;5:593–9.
24. Pirozzi G, Tirino V, Camerlingo R, et al. Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer. Oncol Rep. 2013;29:1763–8.
25. Farace F, Massard C, Vimond N, et al. A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer. 2011;105:847–53.
26. Igawa S, Gohda K, Fukui T, et al. Circulating tumor cells as a prognostic factor in patients with small cell lung cancer. Oncol Lett. 2014;7:1469–73.